# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-23-025439
**Filing Date:** 2023-3
**Character Count:** 4418
**Document Hash:** 94032f8a65dbabf3b6db8b581364b686
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-025439.hdr.sgml**: 20230508

**ACCESSION NUMBER**: 0001213900-23-025439

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

**INmune Bio Inc.** 

**225 NE Mizner Blvd, Suite 640**

**Boca Raton, FL 33432**

**Tel: (858) 964 3720**

March 31, 2023

Ms. Vanessa Robertson and Mr. Kevin Vaughn

Division of Corporation Finance Office of Life Sciences

Securities and Exchange Commission

100 F Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **INmune Bio Inc.** |
|  | **Form 10-K for the fiscal year ended December 31, 2022 Filed March 2, 2023** |
|  | **File No. 001-38793** |

---

Dear Ms. Robertson and Mr. Vaughn:

On behalf of INmune Bio Inc. (the "Company"), this letter responds to comments provided by the staff of the Division of Corporation Finance (the "Staff"), of the Securities and Exchange Commission (the "Commission") provided to the undersigned on March 28, 2023, regarding the Company's Annual Report on Form 10-K (the "Annual Report"), which was filed with the Commission on March 2, 2023.

For convenience, the Staff's comments have been restated below and the Company's responses are set out immediately under the restated comments. Unless otherwise indicated, defined terms used herein have the meanings set forth in the Annual Report.

<u>Form 10-K for the fiscal year ended December 31, 2022</u>

<u>Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations</u>

<u>Research and Development, page 68</u>

1. **You disclose on page 64 that you track outsourced development costs by product candidate or development program, but you do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs. Please revise your future filings to address the following regarding your research and development expense:** 

● **Revise to separately quantify the research and development costs tracked during each** **period presented for each of your key research and development projects.** 

● **For all other research and development expenses, provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. quantify by nature or type of expense).** 

● **Separately quantify the amount of tax credits that are recorded during the period as a reduction to research and development expense.** 

● **The total of costs broken out should reconcile to total research and development expense on the Statements of Operations.** 

Response: The Company acknowledges the Staff's comment and respectfully advises the Staff that it will revise future filings with the SEC to separately quantify the research and development costs tracked during each period for each key research and development projects, provide additional quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred for all other research and development expenses incurred, separately quantify the amount of tax credits that are recorded during the period as a reduction to research and development expense and reconcile the total of costs broken out to total research and development expense on the Statement of Operations.

Please do not hesitate to contact our counsel Thomas Rose at (212) 930-9700 of Sichenzia Ross Ference LLP with any questions or comments regarding this correspondence. Thank you.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| INmune Bio Inc. | INmune Bio Inc. |
| By: | /s/ David Moss |
|  | David Moss |
|  | Chief Financial Officer |

---

cc: Thomas Rose, Esq., Sichenzia Ross Ference LLP